Your browser doesn't support javascript.
SARS-CoV-2 genetic diversity: Its impact on vaccine efficacy.
Lina, B; Bauer, J.
  • Lina B; Laboratoire de virologie, Institut des Agents Infectieux, CHU Lyon, Lyon, France.
  • Bauer J; Service Universitaire des Maladies Infectieuses et du Voyageurs, CH Dron, 59200 Tourcoing, France. Electronic address: bauerjules@gmail.com.
Infect Dis Now ; 52(8S): S2-S3, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2028080
ABSTRACT
SARS CoV 2 S-glycoproteins play a crucial role in the entry steps of viral particles. Due to their surface location, they are the main target for host immune responses and the focus of most vaccine strategies. The D614G mutation identified in late January became dominant during March 2020, rendering SARS-CoV-2 more infectious. In April 2020, the Alpha, Beta and Gamma variants emerged simultaneously in Asia, South Africa, and South America, respectively. They were 1.6 to 2 times more transmissible than the ancestral strain. The currently dominant Omicron variant (BA.2) is not a direct descendant from the D614G lineage, but rather emerged from the BA.1 variant (as did BA.4 and BA.5). It is substantially different from all the other variants. It presents significantly reduced susceptibility to antibody neutralization after 2 doses of mRNA-vaccine, neutralizing titers to Omicron are 41 to 84 times lower than neutralization titers to D614G. That said, a booster dose of mRNA-vaccine increases Omicron neutralization titers and reduces the risk of severe infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Infect Dis Now Year: 2022 Document Type: Article Affiliation country: J.idnow.2022.09.008

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Infect Dis Now Year: 2022 Document Type: Article Affiliation country: J.idnow.2022.09.008